Live Quote · NASDAQOPNTHealthcare· Biotechnology

Opiant Pharmaceuticals, Inc.

$20.65 0.00%(+$0.00)
TickerSpark Score
82/100
Strong
83
Valuation
55
Profitability
100
Growth
72
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPNT research report →

52-Week Range66% of range
Low
$7.34
Current
$20.65
High
$27.36
Company Overviewwww.opiant.com

About the company

Opiant Pharmaceuticals, Inc. functions as a specialized pharmaceutical enterprise, primarily focused on inventing remedies for both various addictions and drug overdoses. A key product in their current portfolio is NARCAN nasal spray, which provides a critical solution for counteracting opioid overdoses.

CEO
Roger Crystal
IPO
2007
Employees
37
HQ
Santa Monica, CA, US

Price Chart

-28.79% · this period
$29.00$19.19$9.38Mar 01Aug 30Mar 01
Valuation
Market Cap
$108.80M
P/E
30.37
P/S
2.67
P/B
1.96
EV/EBITDA
15.10
Div Yield
0.00%
Profitability
Gross Margin
77.74%
Op Margin
12.66%
Net Margin
7.39%
ROE
7.31%
ROIC
8.00%
Growth & Income
Revenue
$40.73M · 48.62%
Net Income
$3.01M · 261.69%
EPS
$0.68 · 254.55%
Op Income
$5.16M
FCF YoY
192.63%
Performance & Tape
52W High
$27.36
52W Low
$7.34
50D MA
$20.50
200D MA
$14.79
Beta
0.83
Avg Volume
72.36K

Get TickerSpark's AI analysis on OPNT

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Mar 2, 23Silver Gabrielle Alisonsell21,343
Mar 2, 23Silver Gabrielle Alisonsell2,500
Mar 2, 23Silver Gabrielle Alisonsell2,500
Mar 2, 23Silver Gabrielle Alisonsell2,000
Mar 2, 23Silver Gabrielle Alisonsell2,500
Mar 2, 23Silver Gabrielle Alisonsell2,500
Mar 2, 23Collard Craig Asell53,822
Mar 2, 23Collard Craig Asell2,000
Mar 2, 23Collard Craig Asell2,500
Mar 2, 23Collard Craig Asell5,000
Coverage · OPNT

Our OPNT coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on OPNT yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate OPNT report →
Internal Compare

Similar companies

Peers in the same neighborhood.